A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Polatuzumab Vedotin And Lenalidomide In Patients With Relapsed Or Refractory Follicular Or Diffuse Large B-Cell Lymphoma

Brief description of study

If you have been diagnosed with Relapsed Or Refractory Follicular Or Diffuse Large B-Cell Lymphoma, you may be qualified to participate in this phase Ib/II stduy. The main goal of this study is to test the safety of obinutuzumab or rituximab in combination with polatuzumab vedotin and lenalidomide at different dose levels and to find out what effects, good and/or bad, the study treatment has on you and your Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL).


Clinical Study Identifier: s15-01128
ClinicalTrials.gov Identifier: NCTs15-01128


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.